Tiziana Life Sciences Ltd. develops intranasal foralumab, a fully human anti-CD3 monoclonal antibody, as a clinical-stage biotechnology company focused on neuroinflammatory and neurodegenerative diseases. News for TLSA centers on clinical and preclinical data for intranasal anti-CD3 therapy, including non-active secondary progressive multiple sclerosis, Multiple System Atrophy, Alzheimer’s disease, ALS, Long COVID-associated neuroinflammation, and age-related cognitive decline.
Company updates also cover biomarker work involving CSF proteomics, TSPO-PET and microglial activation, peer-reviewed publications, scientific conference presentations, expanded-access observations, and financing actions such as registered direct offerings of ordinary shares and warrants.
Tiziana Life Sciences plc (NASDAQ: TLSA) announced the court's sanction of its scheme to reorganize into Tiziana Life Sciences Ltd, a Bermuda-incorporated parent company. The scheme, effective on 20 October 2021, includes a two-for-one share consolidation to enhance share value comparability on NASDAQ. Key dates include the last dealings in Old Tiziana shares on 20 October 2021 and trading commencement for New Tiziana shares on 21 October 2021. The company remains focused on developing therapeutics for oncology, inflammation, and infectious diseases.
Tiziana Life Sciences (Nasdaq: TLSA) recently reported that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, acquired 100,000 ordinary shares at 52p each. This purchase increased Cerrone's ownership from 34.078% to 34.129%, just above the 1% threshold set by the UK Takeover Code. Tiziana Life Sciences, focused on innovative therapeutics for oncology and inflammatory diseases, is set to initiate Phase 2 studies for its anti-CD3 monoclonal antibody, Foralumab, for treating Crohn's Disease and multiple sclerosis, furthering its pipeline of treatment options.
Tiziana Life Sciences Plc has initiated a strategic restructuring, transitioning to Tiziana Life Sciences Ltd, a Bermuda-based parent company. This move was approved by Scheme Shareholders with 99.11% support at the Court Meeting and a requisite majority at the General Meeting. The Scheme is pending court sanction on October 19, 2021, with an expected effective date of October 21, 2021. The transition will involve the delisting of Old Tiziana shares from the London Stock Exchange and NASDAQ, paving the way for trading of New Tiziana shares.
Tiziana Life Sciences (NASDAQ: TLSA) announced its interim results for the six months ending June 30, 2021, highlighting significant advancements in therapeutic clinical programs. The Phase 1 study of Foralumab demonstrated immunomodulatory effects, while a study in Brazil showed promising outcomes for COVID-19 patients. The company signed an agreement for a Phase 2 study in severe COVID-19 cases and initiated a study for multiple sclerosis. Financially, Tiziana reported a loss of £12.59 million, with R&D expenses increasing to £12.6 million. The firm had cash reserves of £38.6 million at the period's end.
Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) will host a conference call on September 8, 2021, at 4:15 p.m. ET to discuss its exclusive license agreement for evaluating Foralumab, a novel anti-CD3 monoclonal antibody, alongside CAR T candidates for cancer treatment. Interested parties can join via a toll-free line or webcast. A replay will be available until September 22, 2021. Foralumab is recognized for its safety profile in treating autoimmune diseases, making it a significant development in biotechnology.
Tiziana Life Sciences plc (NASDAQ: TLSA) announced the initiation of a strategic plan to change its corporate structure by establishing Tiziana Life Sciences Ltd in Bermuda as its ultimate parent company. This restructuring, carried out through a scheme of arrangement, aims to enhance the organization’s operational efficiency. Shareholders are invited to virtual meetings on September 27, 2021, to vote on the scheme. Key dates include the effective date for the scheme on October 21, 2021, and the delisting of Old Tiziana Shares and ADSs on the same day.
Precision BioSciences (Nasdaq: DTIL) has secured an exclusive license from Tiziana Life Sciences (Nasdaq: TLSA) to utilize foralumab, a human anti-CD3 monoclonal antibody, as a lymphodepletion agent in its allogeneic CAR T therapy development. The collaboration aims to enhance the therapeutic effectiveness of CAR T cells by improving their tolerance and long-term persistence. Precision will oversee the development and commercialization of foralumab, providing Tiziana with upfront, milestone, and royalty payments.
Precision BioSciences has secured an exclusive license for Tiziana Life Sciences’ anti-CD3 monoclonal antibody, Foralumab, to evaluate its use as a lymphodepletion agent alongside its allogeneic CAR T therapies for cancer treatment. This collaboration aims to enhance the efficacy of CAR T cell therapies by potentially improving their durability and clinical outcomes. Precision will assume development and commercialization duties, while Tiziana will receive upfront and milestone payments along with royalties.
Tiziana Life Sciences plc (NASDAQ: TLSA) announced a strategic reorganization to establish Tiziana Life Sciences Ltd, a Bermuda-incorporated parent company. This change aims to align the company's listing with its primary US operations and facilitate a direct NASDAQ listing. Old Tiziana shareholders will exchange their shares for New Tiziana Shares at a 2-for-1 ratio, and Old Tiziana will then delist from the FCA and London Stock Exchange. The restructuring is expected to enhance liquidity and reduce costs for shareholders, with details of the scheme and necessary approvals to be communicated soon.
Tiziana Life Sciences (TLSA) announced the successful results of its pilot study on Foralumab, an intranasal anti-CD3 monoclonal antibody for COVID-19 treatment. The study showed a significant reduction in lung inflammation and pro-inflammatory biomarkers, including IL-6 and CRP. Treatment was well-tolerated with only mild adverse events reported. Following this, Tiziana plans to initiate a Phase 2 study in Brazil to further evaluate Foralumab's safety and efficacy in hospitalized COVID-19 patients. The promising data suggests a potential therapeutic benefit for immune hyperactivity in severe cases.